As per MRFR analysis, the US Theranostics Market Size was estimated at 1.72 (USD Billion) in 2023. The US Theranostics Market is expected to grow from 2.35 (USD Billion) in 2024 to 8.35 (USD Billion) by 2035. The US Theranostics Market CAGR (growth rate) is expected to be around 12.216% during the forecast period (2025 - 2035).
The growing need for individualized therapy and developments in molecular diagnostics are driving the substantial expansion of the US theranostics market. The increasing incidence of chronic illnesses like cancer and heart disease, which call for tailored treatments that can be combined with related diagnostic procedures, is one of the major factors propelling the market. The US regulatory environment is also changing to facilitate the creation and authorization of theranostic drugs, with organizations advocating for routes that accelerate the combination of treatments and diagnostics. Clinical researchers, labs, and pharmaceutical corporations are collaborating and innovating because of this favorable atmosphere.
Increased integration of AI and machine learning in diagnostic procedures, which improves accuracy and efficiency, is one opportunity to investigate in the US theranostics sector. Liquid biopsy methods are also gaining popularity since they offer non-invasive ways to identify illnesses and track how well treatments are working. As customized solutions for specialized patient populations gain traction, the focus on rare and orphan diseases further opens up opportunities for theranostics. Value-based care models, which promote the use of interventions that clearly improve patient outcomes in relation to costs, have become more and more popular in recent years.
Healthcare providers are increasingly embracing these integrated approaches as a result of increased understanding of theranostics' advantages. Research and development initiatives that are in line with the particular requirements of the US healthcare system are also made easier by the growing collaborations between biotech companies and academic institutions. This general pattern suggests a changing environment in which theranostics is increasingly playing a crucial role in contemporary American medical practice.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The US Theranostics Market is experiencing significant growth due to the rising prevalence of chronic diseases, particularly cancer and cardiovascular diseases. According to the Centers for Disease Control and Prevention (CDC), chronic diseases account for 70% of deaths in the United States. With approximately 1.9 million new cancer cases projected in a recent year, organizations such as the American Cancer Society are pushing for innovative treatment methods. Theranostics, which provides individualized treatment through targeted therapies, is poised to capitalize on this urgent need.
As demographic trends indicate an aging population, the demand for effective theranostic solutions is anticipated to escalate. The CDC also notes a year-on-year increase in chronic disease-related treatment costs, reinforcing the urgency for targeted and effective therapeutics that can be facilitated by theranostic advancements.
The technological advancements in diagnostic tools and imaging technologies are significant drivers contributing to the growth of the US Theranostics Market. New technologies enable more precise diagnostics, thus improving patient management. The FDA has approved numerous advanced genomic testing methods, which allow for more tailored treatments based on individual patient profiles. For instance, next-generation sequencing (NGS) and liquid biopsy technologies have been instrumental in this transformation.
Recent advancements reported by major health institutions indicate that these technologies can help in accurately identifying specific mutations that govern cancer treatment, leading to better patient outcomes. Such innovation not only enhances the efficacy of therapies but also supports the broader adoption of theranostics in clinical settings.
There is a growing investment focus on personalized medicine within the US healthcare sector. According to the National Institutes of Health (NIH), funding for research into personalized therapies has been steadily increasing, with billions allocated towards understanding genetic variations in diseases. Organizations like the Personalized Medicine Coalition are actively promoting the value of personalized medicine, which emphasizes the delivery of targeted therapies to patients based on their unique genetic profiles.
This shift towards personalized medicine aligns perfectly with the theranostics model, which combines diagnostics and therapeutics. The increasing understanding and technological capabilities surrounding biomarkers are attracting significant investments, driving growth within the US Theranostics Market, as these investments support innovative approaches for disease treatment.
With rising healthcare costs in the US, there is an increasing demand for cost-effective healthcare solutions, which theranostics can efficiently provide. The National Health Expenditure Accounts (NHEA) report indicated that healthcare spending in the US reached approximately $4.1 trillion, urging a re-evaluation of treatment strategies. Theranostics offers a cost-efficient avenue through its targeted approach, which reduces unnecessary treatments and associated costs.
By ensuring that patients receive only the necessary therapies based on their specific conditions, healthcare systems can save significant funds. The integration of theranostics is increasingly seen as a solution to enhance cost-effectiveness while improving patient outcomes, making it a key driver in the growing US Theranostics Market.
The US Theranostics Market encompassing the Application segment from 2019 to 2032 is positioned for robust growth, driven by advancements in personalized medicine and targeted therapies. This market is characterized by significant contributions from multiple areas, including Oncology, Neurology, Cardiology, and Infectious Diseases. Oncology is particularly noteworthy as it represents a significant portion of the overall market due to the rising prevalence of cancer and the growing demand for tailored treatment options. Innovative therapies that combine diagnostics and therapeutics are being developed, yielding improved patient outcomes and ensuring that the right treatment is given to the right patient at the right time.
Neurology is also gaining traction within the US Theranostics Market, spurred by increased recognition of neurological disorders such as Alzheimer's and Parkinson's disease, which require specialized diagnostics and therapeutic approaches to enhance patient management and care. Moreover, Cardiology is emphasizing the need for theranostic approaches to address heart diseases which remain among the leading causes of mortality in the United States, highlighting the significance of personalized treatment strategies to improve cardiovascular health.
Infectious Diseases is rapidly evolving within the market, especially with the ongoing advancements in molecular diagnostics, which are crucial for tracking infections and guiding appropriate therapy, reflecting the surging need for precision in treatment amidst rising global health concerns. The adoption of theranostic applications across these areas is amplified by the increasing prevalence of chronic conditions, technological advancements, and the urgency for efficient healthcare solutions. The US Theranostics Market data indicates that innovative technologies such as AI and machine learning are being integrated into diagnostic tools, facilitating swift and accurate treatment decisions.
Collectively, these trends underscore the multidimensional growth potential of the US Theranostics Market, propelled by the convergence of diagnostics and therapeutics across diverse medical fields. Furthermore, the ongoing investments in research and development supported by governmental health initiatives are anticipated to play a vital role in reinforcing the US position as a leader in theranostics, affecting overall market dynamics and segmental advancements in the future.
The US Theranostics Market thereby lays promising groundwork for comprehensive health solutions that effectively meet the evolving demands of healthcare providers and patients alike, presenting myriad opportunities for stakeholders engaged in therapeutic innovation.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The US Theranostics Market, encompassing the Technology segment from 2019 to 2032, signifies a robust evolution, with various critical fields driving innovation. Within this framework, Genomics plays an increasingly pivotal role, helping in personalized medicine by tailoring treatments based on genetic profiles. Proteomics focuses on the large-scale study of proteins, which is essential for understanding disease mechanisms and discovering biomarkers for diagnostics. Metabolomics adds another layer by analyzing chemical processes involving metabolites, thus providing valuable insights into the metabolic changes associated with diseases.
Biomarkers are vital in this arena as well, serving as indicators for treatment responses and disease progression. The integration of these technologies not only enhances the understanding of complex diseases but also fosters the development of targeted therapies, contributing to improved patient outcomes. The growth in the US Theranostics Market is fueled by advancements in technology, increased investments in research, and a rise in cancer and chronic diseases, creating significant opportunities for innovation and development in these segments.
The US Theranostics Market exhibits a robust structure with the End User segmentation highlighting significant contributions from Hospitals, Diagnostic Laboratories, and Research Institutes. Hospitals are pivotal in this market, as they serve as the primary point of care, integrating advanced theranostic technologies into clinical workflows to enhance patient outcomes. Diagnostic Laboratories play a crucial role by providing essential testing services that facilitate personalized medicine, thus driving the demand for theranostic applications. Research Institutes are vital for innovation, focusing on developing new diagnostic and therapeutic techniques that can be translated into clinical practice.
Together, these segments contribute to the overall growth of the US Theranostics Market, driven by increased healthcare spending and advancements in precision medicine, while challenges such as regulatory hurdles and the need for widespread adoption remain. With the ongoing rise in chronic diseases, the importance of theranostics is likely to grow, opening up further opportunities in this dynamic industry. The market growth in these segments underscores the significance of targeted and personalized treatments, demonstrating their impactful role in enhancing therapeutic efficacy and patient care in the United States.
The US Theranostics Market is positioned for notable growth across various product types, notably Instruments, Reagents, and Software. Instruments play a crucial role, as they facilitate precise diagnostics essential for personalized therapy, indicating their significant contribution to the healthcare sector in the US. Reagents also play a vital role by providing necessary chemical substances for therapeutic diagnostics, which enhances the accuracy of treatment plans. Meanwhile, Software is becoming increasingly important in this market, enabling data management and analysis for better decision-making regarding patient care.
As the US government continues to support advances in precision medicine and theranostics through various health initiatives, there is a clear trend toward integrating these product types. Overall, the US Theranostics Market showcases a vibrant landscape driven by technological advancements and the growing emphasis on personalized medicine, fostering a supportive environment for instruments, reagents, and software to thrive. This market is characterized by opportunities for innovation and growth, aligning well with ongoing healthcare demands.
The US Theranostics Market is characterized by its dynamic landscape, influenced by a blend of innovation, regulatory frameworks, and competitive strategies. This sector, which merges therapeutic and diagnostic advancements, has witnessed significant growth due to the rising demand for personalized medicine. Stakeholders in this market are increasingly focused on enhancing patient outcomes through the development of targeted therapies that are accompanied by predictive diagnostics, fostering a more precise treatment paradigm. The competitive environment features a mix of established pharmaceutical companies and emerging biotechnology firms, all vying for technological supremacy and market share.
Investment in research and development is a crucial factor driving competition, with players continuously striving to improve their offerings through strategic collaborations, acquisitions, and the integration of advanced technologies into their product pipelines. In the context of the US Theranostics Market, Qiagen has established a robust presence marked by a commitment to providing innovative solutions that enhance the detection and characterization of diseases.
The company has developed a diverse portfolio consisting of molecular diagnostics and sample preparation technologies that are pivotal for the successful implementation of theranostic approaches. Qiagen’s strengths lie in its ability to deliver high-quality products that meet regulatory standards, enabling healthcare professionals to make informed decisions regarding patient treatment. The company excels in its partnerships with other entities within the healthcare ecosystem, thereby enhancing its reach and influence in the market. This strategic positioning enables Qiagen to leverage its capabilities and maintain a competitive edge in an increasingly crowded market space.
Bristol Myers Squibb is a renowned player in the US Theranostics Market, recognized for its innovative therapies and commitment to advancing patient care. The company's key products in the oncology space, particularly targeted treatments, align closely with the principles of theranostics, as they often require companion diagnostics for optimal patient selection. Bristol Myers Squibb's strengths include its extensive research footprint, which enables the continuous development of therapies informed by robust clinical data. The company has undertaken several mergers and acquisitions to bolster its capabilities and expand its portfolio, further enhancing its competitive standing within the US market.
By focusing on precision medicine, Bristol Myers Squibb aims to address critical unmet needs in various therapeutic areas, thereby solidifying its role as a leader in the theranostics arena. The alignment of its product offerings with the growing demand for personalized healthcare solutions underscores its strategic vision within this vital sector.
The US Theranostics Market is currently experiencing significant developments and shifts. Recently, companies like Qiagen and OncoOne have published advancements in personalized medicine, showcasing the increasing emphasis on tailored therapies based on genetic profiling. In August 2023, Guardant Health announced a partnership with Merck to enhance their precision oncology approach, focusing on liquid biopsy technology which underscores a growing trend in non-invasive diagnostic methods.
Furthermore, in July 2023, NeoGenomics reported a strategic expansion of its testing services to better serve oncology providers, reflecting the rising demand for more comprehensive genomic testing solutions. In terms of financial dynamics, Roche's acquisition of GenMark Diagnostics in March 2021 has strengthened its position in molecular diagnostics, aligning with the increasing investment in theranostics.
The market's valuation is projected to grow substantially as more companies like Thermo Fisher Scientific and Caris Life Sciences are ramping up R&D efforts and collaborations aimed at integrating advanced diagnostics with treatment strategies. The US regulatory landscape continues to evolve, with the FDA providing clearer pathways for approving innovative theranostic agents, fueling robust market growth in this sector.
| Report Attribute/Metric | Details |
| Market Size 2023 | 1.72(USD Billion) |
| Market Size 2024 | 2.35(USD Billion) |
| Market Size 2035 | 8.35(USD Billion) |
| Compound Annual Growth Rate (CAGR) | 12.216% (2025 - 2035) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Qiagen, Bristol Myers Squibb, NeoGenomics, Guardant Health, Personal Genome Diagnostics, Novartis, Thermo Fisher Scientific, OncoOne, Roche, Genomic Health, Caris Life Sciences, Abbott Laboratories, Merck and Co., Illumina, NantHealth |
| Segments Covered | Application, Technology, End User, Product Type  |
| Key Market Opportunities | Precision medicine advancements, Rising cancer prevalence, Increased R investment, Growing demand for personalized treatments, Expanding companion diagnostics market |
| Key Market Dynamics | Increasing demand for personalized medicine, Advancements in molecular diagnostics, Rising prevalence of chronic diseases, Growing investment in R, Expanding regulatory approvals for therapies |
| Countries Covered | US |
Frequently Asked Questions (FAQ) :
The US Theranostics Market is expected to be valued at 2.35 USD Billion in 2024.
By 2035, the US Theranostics Market is anticipated to reach a valuation of 8.35 USD Billion.
The US Theranostics Market is expected to exhibit a CAGR of 12.216% from 2025 to 2035.
The oncology segment is expected to dominate, with a valuation of 1.1 USD Billion in 2024.
The neurology segment is forecast to reach 2.5 USD Billion in the US Theranostics Market by 2035.
Key players include Qiagen, Bristol Myers Squibb, NeoGenomics, and Guardant Health among others.
The cardiology segment is expected to be valued at 1.5 USD Billion in 2035.
The infectious diseases segment is valued at 0.15 USD Billion in the US Theranostics Market in 2024.
The ongoing advancements in personalized medicine and diagnostics create significant growth opportunities.
Emerging trends such as precision medicine are driving substantial growth in the US Theranostics Market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Analyst Explore the profile of garvit vyas, one of our esteemed authors at market research future, and access their expert research contributions in the field of market research and industry analysis
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
